Table 2. Oncology Trial Participation by Cancer Type and Race and Ethnicity.
| Cancer type race and ethnicity | Clinical trial participation | |
|---|---|---|
| No. of patients/total No. in group (%) | Adjusted hazard ratio (95% CI)a | |
| Advanced non–small cell lung cancer | ||
| Black | 97/2496 (3.9) | 0.45 (0.37-0.56) |
| Latinx | 58/993 (5.8) | 0.74 (0.57-0.96) |
| White | 1303/17 472 (7.5) | 1 [Reference] |
| Metastatic breast cancer | ||
| Black | 65/1503 (4.3) | 0.67 (0.52-0.87) |
| Latinx | 34/1047 (3.2) | 0.45 (0.32-0.64) |
| White | 464/7362 (6.3) | 1 [Reference] |
| Metastatic colorectal cancer | ||
| Black | 75/1488 (5.0) | 0.74 (0.58-0.94) |
| Latinx | 43/1222 (3.5) | 0.46 (0.34-0.63) |
| White | 537/7886 (6.8) | 1 [Reference] |
| Multiple myeloma | ||
| Black | 45/938 (4.8) | 0.69 (0.50-0.95) |
| Latinx | 15/379 (4.0) | 0.61 (0.37-1.00) |
| White | 184/3031 (6.1) | 1 [Reference] |
| Metastatic pancreatic cancer | ||
| Black | 25/487 (5.1) | 0.54 (0.36-0.81) |
| Latinx | 16/332 (4.8) | 0.46 (0.27-0.77) |
| White | 370/3775 (9.8) | 1 [Reference] |
| Overall | ||
| Black | 307/6912 (4.4) | 0.57 (0.51-0.65) |
| Latinx | 166/3973 (4.2) | 0.54 (0.46-0.63) |
| White | 2858/39 526 (7.2) | 1 [Reference] |
a
Models were adjusted for clinical characteristics (age [continuous], gender, Eastern Cooperative Oncology Group performance status, year of diagnosis), as appropriate, with White race as the reference. Racial and ethnic groups were mutually exclusive. Separate models were estimated by cancer using a stratified approach.